Scarica l'app Stockscreener
4.00
5.44%
-0.23
Dopo l'orario di chiusura:
4.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.23
Aprire:
$4.2
Volume 24 ore:
263.54K
Relative Volume:
0.56
Capitalizzazione di mercato:
$377.28M
Reddito:
$35.11M
Utile/perdita netta:
$-79.20M
Rapporto P/E:
-0.9224
EPS:
-4.3367
Flusso di cassa netto:
$-88.62M
1 W Prestazione:
-6.76%
1M Prestazione:
-4.76%
6M Prestazione:
+9.29%
1 anno Prestazione:
+23.46%
Intervallo 1D:
$3.97
$4.21
Intervallo di 1 settimana:
$3.97
$4.60
Portata 52W:
$1.35
$4.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Nome
X 4 Pharmaceuticals Inc
Settore
Industria
Telefono
857-529-8300
Indirizzo
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
4.00 | 398.97M | 35.11M | -79.20M | -88.62M | -4.3367 |
VRTX
Vertex Pharmaceuticals Inc
|
450.41 | 114.99B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
712.87 | 75.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
822.13 | 49.92B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.45 | 38.92B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.47 | 31.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-09 | Iniziato | Guggenheim | Buy |
| 2025-12-05 | Ripresa | Stifel | Buy |
| 2023-12-12 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | Ripresa | B. Riley Securities | Buy |
| 2022-12-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-12 | Iniziato | Piper Sandler | Overweight |
| 2019-12-23 | Iniziato | Oppenheimer | Outperform |
| 2019-12-18 | Iniziato | ROTH Capital | Buy |
| 2019-12-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-12-05 | Iniziato | B. Riley FBR | Buy |
| 2019-06-07 | Iniziato | Stifel | Buy |
| 2019-06-05 | Iniziato | Cowen | Outperform |
Mostra tutto
X 4 Pharmaceuticals Inc Borsa (XFOR) Ultime notizie
Here is Why X4 Pharmaceuticals (XFOR) is Among the Unrivaled Penny Stocks to Buy Now - Yahoo Finance
X4 Pharmaceuticals (XFOR) corrects director nominee and expands equity plan - Stock Titan
X4 Pharma CFO Kirske sells $72,820 in common stock - Investing.com
X4 Pharmaceuticals (XFOR) CFO sells shares to cover tax obligation - Stock Titan
[144] X4 Pharmaceuticals, Inc SEC Filing - Stock Titan
[8-K] X4 Pharmaceuticals, Inc Reports Material Event - Stock Titan
5 Unrivaled Penny Stocks to Buy Now - Insider Monkey
XFOR (X4 Pharmaceuticals) beats Q1 2026 EPS estimates by 21.6 percent, shares climb 3 percent.Collaborative Trading Signals - newser.com
How X4 Pharmaceuticals (XFOR) is positioning for the next five years (Bearish Sentiment) 2026-05-08Shared Momentum Picks - newser.com
Major holder Artal group converts LXRX (LXRX) Series B preferred into 20.4M common shares - Stock Titan
Best Pharmaceutical Stocks for 2026 and How to Invest - The Motley Fool
CapEx per share of X4 Pharmaceuticals, Inc. – FWB:48Q0 - TradingView
EBIT per share of X4 Pharmaceuticals, Inc. – FWB:48Q0 - TradingView
X4 pharmaceuticals incmay offer up to $300 million of common stock, preferred stock, debt securities, warrants, and/or unitsSEC filing - marketscreener.com
X4 Pharmaceuticals IncMay Offer Up To $300 Million Of Common Stock, Preferred Stock, Debt Securities, Warrants, And/Or UnitsSEC Filing - TradingView
X4 Pharmaceuticals (NASDAQ: XFOR) files $300M shelf; $75M ATM with Jefferies - Stock Titan
X4 Pharmaceuticals, Inc. Q1 2026 Financial Results and Forward-Looking Statements – Quarterly Report Highlights - Minichart
X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
X4 Pharmaceuticals: Q1 Earnings Snapshot - KING5.com
X4 Pharmaceuticals Reports Positive Updates on 4WARD Phase 3 Trial and European Commission Approval for XOLREMDI - Quiver Quantitative
EU authorizes first WHIM syndrome treatment as X4 trial nears enrollment - Stock Titan
X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance
EU approves XOLREMDI as X4 Pharmaceuticals (NASDAQ: XFOR) reports Q1 loss - Stock Titan
X4 Pharmaceuticals Inc (XFOR) - MSN
NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA - ACCESS Newswire
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026 - Business Wire
MSN Money - MSN
Processa (PCSA) CAO Wendy Guy buys 1,748 shares in open-market trade - Stock Titan
Seven new Xenon hires get stock awards priced at $56.04 - Stock Titan
Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity - The Manila Times
Europe authorizes first drug for patients with relentless hunger - Stock Titan
XFOR Stock Price, Quote & Chart | X4 PHARMACEUTICALS INC (NASDAQ:XFOR) - ChartMill
Ionis (NASDAQ: IONS) EVP sells 1,626 shares under Rule 10b5-1 plan - Stock Titan
Fierce Biotech Layoff Tracker 2026: Autolus decreases headcount by 13%; Replimune reduces staff - Fierce Biotech
X4 Pharmaceuticals (XFOR) Stock: Directional Bias Review | Q4 2025: Earnings Beat EstimatesCrowd Trend Signals - Newser
$1.9B deal gives Chiesi first oral, on-demand hereditary angioedema treatment - Stock Titan
X4 Pharmaceuticals gets EU approval for WHIM syndrome drug By Investing.com - Investing.com Canada
X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union - The Manila Times
A rare immune disorder gets its first approved treatment across Europe - Stock Titan
Layoff Tracker: Novartis cuts hit New Jersey again, affecting 60 employees - BioSpace
China SXT Pharmaceuticals (SXTC) Co-CEO reports indirect Class B stake - Stock Titan
ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till date - The Economic Times
Recursion Pharmaceuticals (NASDAQ: RXRX) director sells 40K shares under plan - Stock Titan
ROKU (Roku Inc.) tops Q4 2025 EPS estimates by a wide margin, shares rise nearly 4 percent in today’s session.Trending Stock Ideas - Xã Thanh Hà
Is X4 Pharmaceuticals (XFOR) stock a solid choice for investors | Q4 2025: Earnings Beat Estimates - Cổng thông tin điện tử tỉnh Lào Cai
Liquidia Corp.: Prime Candidate For A Takeout By Large Pharma (LQDA) - Seeking Alpha
Tax-driven RSU share sale by KalVista (KALV) CCO Nicole Sweeny - Stock Titan
Tax-related share sale by KalVista (KALV) CEO after RSU vesting - Stock Titan
Can BMY's Growth Portfolio Counter Legacy Drugs Decline in Q1? - TradingView
Is ANIP Stock Undervalued at 10x Forward Earnings and $93 Target? - TradingView
Xenon Pharmaceuticals Reports Positive Phase 3 X-TOLE2 Study Results for Azetukalner in Focal Onset Seizures at AAN 2026 - Quiver Quantitative
X 4 Pharmaceuticals Inc Azioni (XFOR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.96%
0.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):